Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Duobrii (halobetasol/tazarotene) and Skyrizi (risankizumab) are both used to treat plaque psoriasis, but they have some key differences. Duobrii is a topical lotion that combines a corticosteroid and a retinoid, while Skyrizi is an injectable interleukin antagonist. Duobrii is applied once daily directly to the skin, whereas Skyrizi is injected under the skin every 2 to 3 months after initial doses. Duobrii can cause skin irritation and sun sensitivity, and it is not recommended for long-term use due to potential hormone changes. On the other hand, Skyrizi can increase the risk of infections and may cause joint pain and headaches. Skyrizi is also used to treat psoriatic arthritis and Crohn's disease, while Duobrii is specifically for plaque psoriasis. Both Duobrii and Skyrizi are only available as a brand-name medication, making them potentially more expensive. Duobrii can be self-applied, whereas Skyrizi is a biologic medication that can be self-administered at home after proper training.
Duobrii (halobetasol / tazarotene)
Skyrizi (risankizumab)
Duobrii (halobetasol / tazarotene)
Skyrizi (risankizumab)
Summary of Duobrii vs. Skyrizi
Summary for Corticosteroid / Retinoid
Prescription only
Duobrii is a combination medication that contains halobetasol (a corticosteroid) and tazarotene (a retinoid). It's a prescription topical lotion that's FDA-approved to treat plaque psoriasis in adults. The directions for using the medication are to apply a thin amount over the affected area(s) of skin once per day. But avoid putting on the face, groin, and underarms. Side effects aren't common, but can include skin rash and pain at the site of application. Duobrii is brand name only and not available as a generic.